SCHEMBL15549241

SCHEMBL15549241

O=CC1CC(F)(F)C(=O)N1CCc1ccc(C(=O)O)cc1

nearest known ligand 0.64

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ PTGER4 P35408 20/20 0.64
▸ PTGER2 P43116 17/20 0.64
▸ PTGER3 P43115 5/20 0.42
▸ PTGER1 P34995 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28425760 1.00 PTGER4 (0.64) PTGER4PTGER2PTGER3PTGER1
SCHEMBL15587105 0.86 PTGER4 (0.52) PTGER4PTGER2
SCHEMBL16401606 0.86 PTGER4 (0.52) PTGER4PTGER2
SCHEMBL18942726 0.84 PTGER4 (0.57) PTGER4PTGER2PTGER3PTGER1
SCHEMBL16819239 0.79 PTGER4 (1.00) PTGER4PTGER2PTGER3
SCHEMBL22025636 0.79 PTGER4 (0.59) PTGER4PTGER2PTGER3
SCHEMBL22025478 0.79 PTGER4 (0.83) PTGER4PTGER2PTGER3
SCHEMBL22025635 0.79 PTGER4 (1.00) PTGER4PTGER2PTGER3
SCHEMBL15587135 0.79 PTGER4 (0.83) PTGER4PTGER2PTGER3
SCHEMBL19328458 0.79 PTGER4 (1.00) PTGER4PTGER2PTGER3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107802623-B Difluorolactam compositions for EP 4-mediated bone-related diseases and disorders 开曼化学股份有限公司 2020-10-30 — — CN disclosed
CN-106748951-B Difluorolactam compounds as EP4 receptor selective agonists for use in the treatment of EP4 mediated diseases and conditions 开曼化学股份有限公司 2020-07-24 — — CN disclosed
EP-3021879-A2 METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH Cayman Chemical Company, Incorporated (US) 2016-05-25 — — EP disclosed
EP-2875022-A1 DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS Cayman Chemical Company, Incorporated (US) 2015-05-27 — — EP disclosed
EP-2874620-A1 DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS Cayman Chemical Company, Incorporated (US) 2015-05-27 — — EP disclosed
WO-2015009991-A2 METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH CAYMAN CHEMICAL COMPANY, INC. (US) 2015-01-22 — — WO disclosed
WO-2014015247-A1 DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS CAYMAN CHEMICAL COMPANY, INC. (US) 2014-01-23 — — WO disclosed
WO-2014015246-A1 DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS CAYMAN CHEMICAL COMPANY, INC. (US) 2014-01-23 — — WO disclosed
Send feedback